Dillon & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.01M | Sell |
13,344
-392
| -3% | -$206K | 0.95% | 29 |
|
|
2025
Q1 | $8.71M | Sell |
13,736
-163
| -1% | -$103K | 1.29% | 24 |
|
|
2024
Q4 | $9.9M | Buy |
13,899
+374
| +3% | +$266K | 1.37% | 24 |
|
|
2024
Q3 | $14.2M | Buy |
13,525
+878
| +7% | +$923K | 2% | 15 |
|
|
2024
Q2 | $13.3M | Buy |
12,647
+279
| +2% | +$293K | 1.93% | 14 |
|
|
2024
Q1 | $11.9M | Buy |
12,368
+573
| +5% | +$551K | 1.87% | 17 |
|
|
2023
Q4 | $10.4M | Sell |
11,795
-346
| -3% | -$304K | 1.88% | 17 |
|
|
2023
Q3 | $9.99M | Buy |
12,141
+378
| +3% | +$311K | 1.92% | 16 |
|
|
2023
Q2 | $8.46M | Buy |
11,763
+889
| +8% | +$639K | 1.56% | 25 |
|
|
2023
Q1 | $8.94M | Buy |
10,874
+349
| +3% | +$287K | 1.77% | 20 |
|
|
2022
Q4 | $7.59M | Sell |
10,525
-1
| -0% | -$721 | 1.64% | 21 |
|
|
2022
Q3 | $7.25M | Buy |
10,526
+439
| +4% | +$302K | 1.68% | 23 |
|
|
2022
Q2 | $5.96M | Buy |
10,087
+354
| +4% | +$209K | 1.34% | 28 |
|
|
2022
Q1 | $6.79M | Buy |
9,733
+515
| +6% | +$359K | 1.29% | 28 |
|
|
2021
Q4 | $5.83M | Buy |
9,218
+1,362
| +17% | +$861K | 1.02% | 28 |
|
|
2021
Q3 | $4.75M | Buy |
7,856
+1,493
| +23% | +$903K | 0.91% | 30 |
|
|
2021
Q2 | $3.56M | Buy |
6,363
+2,826
| +80% | +$1.58M | 0.7% | 34 |
|
|
2021
Q1 | $1.67M | Buy |
+3,537
| New | +$1.67M | 0.36% | 40 |
|